Morphine oral - CeNeS

Drug Profile

Morphine oral - CeNeS

Alternative Names: Morphine OSAT

Latest Information Update: 15 Oct 2002

Price : $50

At a glance

  • Originator CeNeS Pharmaceuticals
  • Class Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Oct 2002 Discontinued - Clinical-Phase-Unknown for Pain in United Kingdom (PO)
  • 16 Dec 1999 Core Group has merged with CeNeS Limited to form CeNeS Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top